Indian Penicillin G, Rifa-S Import Ban
India has banned all imports of penicillin G and rifampicin intermediates (Rifa-S) for the year 1996-97 (April-March), given the "ample availability" of these products from local supplies, according to a spokeswoman for the Ministry of Chemicals and Fertilizers. The ban takes immediate effect.
Meantime, the Ministry's report for 1994-95 says that India's membership of the World Trade Organization will have no impact on the prices of drugs already on the market; this will be confined to drugs coming to market on the basis of patents granted after the agreement took effect.
The report says India's production of bulk drugs and formulations grew 15% during 1994-95, with exports of the former rising 25% and the latter increasing 20%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze